louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03081221: Verification of Endotracheal Tube Placement With Ultrasonography (USG)
Official title: Verification of Endotracheal Tube Placement With Ultrasonography (USG) in Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intubation
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2017-03-16
Enrollment: 64
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 0-18 age children

Brief summary: The purpose of this study is to verification of Endotracheal Tube Placement with Ultrasonography (USG).

Detailed description: The purpose of this study is to verification of Endotracheal Tube Placement with Ultrasonography (USG). In this study, using of USG during verification will be compared with traditional method.

In traditional methods, after intubation, verification of endotracheal tube placement is done via to monitoring of thorax movement, checking of tube fogging, auscultation of lung and stomach, capnography and radiography.

In USG method, after intubation, verification of endotracheal tube placement is done via to using linear transducer. The probe will be placed transversely and longitudinally on the neck and in front of cricoid cartilage.

So, collected all data from two method will be compared.

Eligibility criteria: Inclusion Criteria:

* applied intubation patients

Exclusion Criteria:

-

Primary outcomes:
measure: Detection of Tube
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Adana
country: Turkey
facility: Cukurova University
Study officials:
References:
Clinical trial NCT02634021: Effect of Loading of Midazolam or Dexmedetomidine on Hemodynamics
Official title: Hemodynamic Change Between Loading of Dexmedetomidine or Midazolam as a Sedative Agents During Knee Arthroscopy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Knee Injuries
Lead sponsor: Konkuk University Medical Center
Sponsor class: OTHER
First posted: 2015-12-17
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Loading dose of dexmedetomidine is related hemodynamic instability such as bradycardia and hypertension.

Detailed description: The investigators hypothesized substitution of loading of dexmedetomidine for midazolam could reduce hemodynamic instability during spinal anesthesia for knee arthroscopy.

Eligibility criteria: Inclusion Criteria:

* patients who were planned to undergo knee arthroscopy under spinal anesthesia

Exclusion Criteria:

* age \< 20 years
* underlying heart, liver or kidney disease
* hypersensitivity to midazolam or dexmedetomidine

Primary outcomes:
measure: change of heart rate
timeFrame: from 1 minute before anesthesia to 1 hr after anesthesia
Secondary outcomes:
measure: change of bispectral index
timeFrame: from 1 minute before anesthesia to 1 hr after anesthesia
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Konkuk University Medical Center
Study officials:
affiliation: Konkuk University Medical Center
name: Seong-Hyop Kim, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03566121: Prediction of the Severity of Female SUI by Measuring New Static and Dynamic Ultrasound Parameters of the Urethra
Official title: Prediction of the Severity of Female SUI by Measuring New Static and Dynamic Ultrasound Parameters of the Urethra
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Incontinence, Urinary
Lead sponsor: CMC Ambroise Paré
Sponsor class: OTHER
First posted: 2018-06-21
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study aims to evaluate the correlation of the ultrasonic functional length of the urethra and the incontinence urinary disorder (IUD). The goal is to predict the severity of the IU by measuring new static and dynamic ultrasound parameters of the urethra.

Detailed description: The urinary incontinence is a disorder which affects 25 to 45% of women. Nowadays, the role of urethral tissue in IUD is not explored although well viewed in perineal ultrasound. Our actual knowledge demonstrates that urodynamic ultrasound is reliable to establish the bladder neck mobility. And the posterior urethral wall mobility was often associated to the stress urinary incontinence. Two elements appeared to indicate the elasticity of the urethral environment: functional length urethral variation and urethral closure angle variation during Valsalva manoeuvres compared to rest. This study aims to evaluate the correlation of the ultrasonic functional length of the urethra and the incontinence urinary disorder for the purpose to predict the severity of this syndrome.

Eligibility criteria: Inclusion Criteria:

* All patients aged over 18 years addressed to pelvic ultrasound

Exclusion Criteria:

* Pregnant
* Post-partum (under 6 month of childbirth)
* Operated for a genitourinary prolapse or/and urinary incontinence
* Utero vaginal symptomatic prolapse
* Overactive bladder ± UI by
* Dysuria
* Severe deep pelvic endometriosis
* Respiratory failure (Unable to perform the Valsalva manoeuvres)
* History of pelvic cancer
* Unable to understand the information communicated

Primary outcomes:
measure: Measurement of ultrasonic urethral length
timeFrame: From 3 to 11 days after gynecological consultation
Secondary outcomes:
Other outcomes:
Locations:
city: Neuilly-sur-Seine
country: France
facility: CMC Hartmann
city: Paris
country: France
facility: Centre Echographie Obstétricale
Study officials:
affiliation: CMC Hartmann
name: Georges BADER, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02836821: Effect of Rifampicin on the Pharmacokinetics of Apatinib
Official title: Effect of Rifampicin on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neoplasms
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2016-07-19
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to investigate potential pharmacokinetic interaction in healthy volunteers when apatinib is administered in combination with rifampicin. Secondary objective is evaluating the safety and tolerability of apatinib alone and when co-administered with rifampicin.


Eligibility criteria: Inclusion Criteria:

* female of non-childbearing potential or male;
* age 18-45 years;
* body mass index 19-24 kg/m2 with total body weight;

Exclusion Criteria:

* clinically significant medical or surgical conditions with the potential to interfere with the absorption, distribution, metabolism or excretion of the study drugs;
* history of alcohol abuse; smoker;
* electrocardiogram(ECG) abnormality;
* blood pressure \>140/90 mmHg;
* treatment with an investigational drug or any known CYP450 enzyme inducing/-inhibiting agents or herbal supplements within 14 days prior to first dose of study medication;
* Subjects were to abstain from using prescription and non-prescription drugs (other than acetaminophen as deemed necessary), vitamins and dietary supplements within 14 days prior to the first dose of study medication and throughout the study.

Primary outcomes:
measure: Area under the plasma concentration versus time curve (AUC) of Apatinib
timeFrame: 0~72h after apatinib administration
Secondary outcomes:
measure: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
timeFrame: From first administration to the seventh day after last administration
measure: Peak Plasma Concentration (Cmax) of Apatinib
timeFrame: 0~72h after apatinib administration
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Xuhui Central Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT01513421: Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection
Official title: Active Versus Non Active Drainage for the Treatment of Infected Intra-abdominal Collection: a Randomized Prospective Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Surgery
Pancreatitis
Diverticulitis
Appendicitis
Keywords: Infected
Intra-abdominal
Collection
Drainage
Percutaneous
Lead sponsor: Centre Hospitalier Universitaire Vaudois
Sponsor class: OTHER
First posted: 2012-01-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: In-hospital patients with infected intra-abdominal collection (primary or secondary to surgery)

Brief summary: The Percutaneous drainage of symptomatic intra-abdominal collection (primary or secondary to surgery)is the treatment of choice in the absence of peritonitis signs. In critically ill patients, this procedure allows to avoid or postpone surgery. In these settings, the percutaneous drain can be either in Active Vacuum Pressure or in Free drainage. However, no prospective trials has assessed the efficiency of these two modalities of drainage in cases of infected intra-abdominal collections. The investigators aimed then to prospectively analyzed the efficiency (in term of infectious control) of drainage under active vacuum pressure vs. free drainage for the treatment of infected intra-abdominal collections.


Eligibility criteria: Inclusion Criteria:

* Infected intra-abdominal collection requiring a percutaneous drainage after surgery or due to a primary intra-abdominal infectious disease (e.g. diverticulitis, appendicitis)
* age over 18 years old
* intra-abdominal collections \>5 cm in diameter with signs of infections on imaging

Exclusion Criteria:

* pregnancy
* age\< 18 years
* signs of peritonitis
* Intensive care unit patients

Primary outcomes:
measure: time of drainage
timeFrame: 90 days after drianage
Secondary outcomes:
measure: Control of infection
timeFrame: up to 7 days after drainage
measure: Timing of antibiotherapy
timeFrame: up to 15 days after drainage
measure: Hospital stay
timeFrame: up to 90 days after drainage
measure: Morbidity related to the procedure
timeFrame: up to 90 days after drainage
measure: in-hospital mortality
timeFrame: up to 90 days after the drainage
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Department of Visceral surgery, CHUV
state: Vaud
Study officials:
affiliation: Department of Visceral surgery (CHUV)
name: Emmanuel Melloul, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Visceral surgery (CHUV)
name: Nicolas Demartines, M.D.
role: STUDY_CHAIR
affiliation: Department of Interventional radiology (CHUV)
name: Alban Denys, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT03177421: Health Information Technology to Improve Bedtime Media Use in Children
Official title: Improving Bedtime Media Use and Sleep Through Health Information Technology
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Sleep Hygiene, Inadequate
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2017-06-06
Enrollment: 60100
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Midway through the study, participants from the control group will be folded into the intervention group.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The objective of this study is to use health information technology to implement and evaluate a counseling recommendation for children who suffer from problematic sleep associated with bedtime media use. Participants will be randomized by clinic to be screened for basic sleep concerns and receive appropriate counseling, or to be screened for sleep concerns and media use, and receive appropriate counseling.

Detailed description: Children and adolescents are increasingly integrating media and technology into daily life. A large body of research has shown poor sleep-related outcomes related to media exposure, especially in evening or bedtime hours - a trend that holds true from infancy to adolescence. Prior research has demonstrated clinic-based interventions can be effective in reducing general screen time. Yet, little work has been done to leverage existing health information technology to adapt bedtime media use guidelines into sustainable counseling interventions. This study will develop, implement, and evaluate a computerized, evidence-based decision support intervention for reducing inappropriate childhood bedtime media use and improving sleep measures.

Eligibility criteria: Inclusion Criteria:

* Attend a participating clinic
* Complete a prescreener form in the clinic

Exclusion Criteria:

* None

Primary outcomes:
measure: Rate of clinician counseling for problematic bedtime media use and sleep problems
timeFrame: Up to 3 years
Secondary outcomes:
measure: Change in bedtime media use following clinician counseling
timeFrame: Up to 3 years
measure: Change in inadequate sleep quantity following clinician counseling
timeFrame: Up to 3 years
measure: Change in daytime sleepiness following clinician counseling
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Eskenazi Health
state: Indiana
city: Indianapolis
country: United States
facility: Riley Hospital for Children
state: Indiana
Study officials:
affiliation: Indiana University - Ped Health Services
name: Randall W. Grout, MD, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00720421: A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.
Official title: A Phase 1, Single Centre, Single Dose, Double-blind, Double-dummy, Four-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effects of AZD7325 on Sedation, Cognition and Electroencephalogram (EEG) in Comparison With Lorazepam in Healthy Male Volunteers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteer
Keywords: Phase I
pharmacodynamic study
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-07-22
Enrollment: 16
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of the study is to determine the effects of the compound AZD7325 as compared to lorazepam on sleepiness, concentration and brain activity.


Eligibility criteria: Inclusion Criteria:

* Healthy male aged 18 to 55 years on screening

Exclusion Criteria:

* Clinically significant illness within 2 weeks before the study start
* Enrollment in another concurrent investigational study or intake of an investigational drug within 30 days or intake of an investigational drug within a period of 5 half lives of that drug prior to the screening visit
* Blood loss in excess of 200 mL within 30 days of Day -2, in excess of 400 mL within 90 days of Day -2, or in excess of 1200 mL within 1 year of Day -2
* Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis

Primary outcomes:
measure: Evaluation of the pharmacodynamic effects of AZD6280 by central nervous system function tests.
timeFrame: Test batteries will be performed at specified times both before and following study drug administration.
Secondary outcomes:
measure: Evaluation and characterization of the pharmacokinetics of AZD6280.
timeFrame: Blood samples will be taken during the study.
Other outcomes:
Locations:
city: Leiden
country: Netherlands
facility: Centre for Human Drug Research
Study officials:
affiliation: CHDR Leiden, the Netherlands
name: J.M.A. Van Gerven, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01509521: The Oxygenation of the Brain During Caesarean Section
Official title: The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Complications; Cesarean Section
Keywords: Spectroscopy, Near-Infrared
Fetal heartrate
Ephedrine
Phenylephrine
Lead sponsor: Naestved Hospital
Sponsor class: OTHER
Collaborators: name: Rigshospitalet, Denmark
First posted: 2012-01-13
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the impact of phenylephrine versus ephedrine on organ perfusion, in women undergoing caesarean section receiving spinal anaesthesia. The organ perfusion is estimated by measuring the maternal cerebral oxygenation by NIRS(Near-infrared spectroscopy)and the foetal heartrate.


Eligibility criteria: Inclusion Criteria:

* Healthy pregnant women
* Over 18 years old
* ASA 1-2
* Undergoing elective caesarean section
* Height over 160 cm or under 180 cm

Exclusion Criteria:

* Allergic reactions to ephedrine or phenylephrine
* High blood levels of bilirubin
* HELPP syndrome
* Preeclampsia (pregnancy-induced hypertension)
* Non singleton pregnancies

Primary outcomes:
measure: Frontal lobe cerebral oxygenation
timeFrame: Participants will be followed for the time in the operation theatre of the hospital stay, an expected average of 1 hour
measure: Foetal heartrate
timeFrame: Participants will be followed for the time in the operation theatre of the hospital stay, an expected average of 1 hour
Secondary outcomes:
measure: Mean arterial pressure
timeFrame: Participants will be followed for the time in the operation theatre of the hospital stay, an expected average of 1 hour
measure: Cardiac output
timeFrame: Participants will be followed for the time in the operation theatre of the hospital stay, an expected average of 1 hour
measure: Umbilical cord pH and Base excess
timeFrame: Blood analysis taken immediately after the the clamping of the umbilical cord, an average of 20 minutes.
Other outcomes:
Locations:
city: Naestved
country: Denmark
facility: Naestved Hospital
Study officials:
affiliation: Naestved Hospital
name: Visti Foss
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chooi C, Cox JJ, Lumb RS, Middleton P, Chemali M, Emmett RS, Simmons SW, Cyna AM. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev. 2020 Jul 1;7(7):CD002251. doi: 10.1002/14651858.CD002251.pub4.
citation: Foss VT, Christensen R, Rokamp KZ, Nissen P, Secher NH, Nielsen HB. Effect of phenylephrine vs. ephedrine on frontal lobe oxygenation during caesarean section with spinal anesthesia: an open label randomized controlled trial. Front Physiol. 2014 Mar 3;5:81. doi: 10.3389/fphys.2014.00081. eCollection 2014.
Clinical trial NCT01986621: Myocardial Injury After Elective Coronary Stenting
Official title: Identification of Patients at Higher Risk for Myocardial Injury or Type 4a Infarction Following Elective Coronary Artery Stenting
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: Percutaneous Coronary Intervention
Cardiac troponin
Antiplatelet therapy
Lead sponsor: University Hospital Heidelberg
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2013-11-18
Enrollment: 530
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with stable or unknown CAD undergoing elective coronary intervention without receiving additional examination, such as biopsy, Ablation or any other procedure that could lead to myocardial injury resulting in elevation of the cardiac Troponin.

Brief summary: This pilot study aims to identify patients at moderate to high risk for peri-procedural (type 4) myocardial infarction or injury after after undergoing an elective coronary intervention (PCI) as measured by high sensitivity troponin T, who might benefit from more potent antiplatelet therapy.


Eligibility criteria: Inclusion Criteria:

* Stable or unknown coronary artery disease (CAD)
* Elective coronary intervention
* Minimum age of 18

Exclusion Criteria:

* Present acute coronary syndrome (ACS)
* Age under 18
* Pregnancy
* Any additional invasive intervention with potential myocardial injury
* Non ACS conditions responsible for elevation of cardiac troponin, such as acute pulmonary artery embolism, myocarditis or tachycardia.

Primary outcomes:
measure: Postprocedural myocardial infarction (type 4a) or injury
timeFrame: up to 72 hours after procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: Department of Cardiology - University Hospital of Heidelberg
Study officials:
affiliation: University Hospital Heidelberg
name: Haitham Abu Sharar, Dr. med.
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Heidelberg
name: Evangelos Giannitsis, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: